Akari <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Faces Nasdaq Delisting Risk Over Minimum Bid Price Compliance
Akari Therapeutics plc has received a notification from Nasdaq indicating that the company is not in compliance with the minimum bid price requirement, which mandates a closing bid price of at least $1.00 per share. The company has 180 calendar days, until May 25, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. If Akari does not meet this requirement by the deadline, it may be eligible for an additional 180-day compliance period if certain conditions are met. Failure to regain compliance could result in the delisting of its American Depositary Shares from the Nasdaq Capital Market, though the company would have the opportunity to appeal any delisting decision.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-025177), on November 26, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。